ALUR, 2018 trial summary

A randomised clinical trial investigating the effect of alectinib versus chemotherapy in ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

        Z

NCT02604342    
2nd line crizotinib failure



Studied treatment oral alectinib at a dose of 600 milligrams (mg) twice daily
taken with food and treatment continued until disease progression, unacceptable toxicity, withdrawal of consent or death
Control treatment chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.



Patients ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Group sizes-9 / -9
PFS measure



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint PFS Design Parallel groups



EndpointX1N1X0N0TE95% CI PFS - -9 - -9 Out of scale0,15[0,08; 0,29] OS - -9 - -9 no data0,22,01,0

Links

press release

press release

ClinicalTrial.gov record NCT02604342



Registering number NCT02604342 (see trial on clinicaltrials.gov)
Code Name

 

All trials of alectinib

Appears in following systematic reviews: